Benefits
Digestive comfort with a papaya fruit concentrate
In a double-blind placebo-controlled trial, people with chronic indigestion took a papaya fruit concentrate 20 ml a day for 40 days. Among those who completed the full period, constipation and bloating were reported less often than with placebo, while the change in heartburn fell short of significance in a small subgroup. The benefits faded after the preparation was stopped.
Antioxidant defense markers in older adults
In a crossover trial, adults without major illness took a fermented papaya preparation 9 g a day for three months. Blood antioxidant protection improved versus placebo, most clearly in a subgroup defined by a GSTM1 gene variant, and a plasma DNA-damage marker improved regardless of genotype. The authors called the findings preliminary. The preparation is linked to its maker, and the group was small.
Oxidative and inflammatory blood markers in a controlled trial
In a randomized controlled trial in a newly diagnosed metabolic-risk population, a fermented papaya preparation 6 g a day for 14 weeks was followed by lower C-reactive protein and shifts in the LDL to HDL ratio and uric acid versus the control group. These are blood markers measured over a few months, not clinical outcomes, and the trial was small.
Immune cell activity in long-term tube-fed older patients
In older patients fed long term through a tube, 30 days of a fermented papaya preparation restored one laboratory measure of immune cell killing activity toward higher levels, while other immune markers did not change and the mix of gut bacteria shifted. This was a small, maker-funded study in a specific hospital population, not healthy users.
Source of antioxidant vitamin C, carotenoids and polyphenols
Papaya fruit, leaf and seed contain vitamin C, carotenoids such as lycopene and beta-carotene, and flavonoid polyphenols. In laboratory tests these compounds scavenge free radicals and quench reactive oxygen species. This describes the fruit's chemistry and lab antioxidant activity; it is not a measured health outcome in people.
Mechanism of action
Fruit enzymes and fiber aid digestion
Papaya fruit naturally contains the protein-digesting enzyme papain plus pectin and other fiber. Papain breaks down dietary protein across a wide pH range and is covered in full on its own page. The fiber adds bulk and can support bowel regularity, which is the proposed basis for the fruit concentrate's effect on constipation and bloating.
Fermentation makes polyphenols easier to absorb
Papaya's polyphenols are mostly large, polymerized molecules that are poorly absorbed from the gut. Fermentation breaks them into small phenolic acids. In one study of a fermented preparation, chemical analysis found these low-molecular-weight phenolic acids and no large polymers, which is offered as why the fermented form may reach the body better than raw fruit.
Plant antioxidants neutralize free radicals
In laboratory work, papaya's vitamin C, carotenoids and flavonoids donate electrons to unstable free radicals and quench reactive oxygen species, and the fruit extracts raise antioxidant-enzyme activity in cell and animal models. How much of this happens in people at supplement doses is not established.
Clinical trials
Double-blind, placebo-controlled trial of a papaya fruit concentrate 20 ml a day for 40 days in people with chronic digestive complaints (Muss et al. 2013, Neuro Endocrinol Lett).
Volunteers with chronic indigestion and gastrointestinal dysfunction; symptom frequency recorded by questionnaire before and after.
Among participants who returned right after the 40-day intake, constipation and bloating improved significantly more with the papaya concentrate than with placebo; heartburn did not reach significance because only 13 people reported it. The improvements were gone in those who returned after a washout delay. The authors concluded the preparation supports normal digestive-tract physiology.
Randomized, placebo-controlled crossover study of a fermented papaya preparation 9 g a day for 3 months with a 6-week washout (Marotta et al. 2006, Ann N Y Acad Sci).
54 elderly patients without major invalidating diseases, split into matched groups and crossed over.
Antioxidant protection in the blood rose significantly with the fermented papaya preparation versus placebo in the subgroup with the null GSTM1 genotype, and a plasma DNA-adduct marker improved regardless of genotype; a leukocyte DNA-oxidation marker rose only in the null-genotype subgroup. The authors called the data preliminary and said the preparation looks promising for antioxidant defense in older people.
Randomized controlled trial of a fermented papaya preparation 6 g a day for 14 weeks in a multi-ethnic newly diagnosed metabolic-risk population (Somanah et al. 2012, Prev Med).
A neo-diabetic Mauritian population recruited at a hospital cardiac center, compared with a control group.
Versus control, C-reactive protein fell significantly, the LDL to HDL ratio changed, and uric acid and serum ferritin improved. These are oxidative and inflammatory blood markers measured over about three months, not clinical endpoints, and the trial was small and conducted in a specific population.
Dose-comparison study of a fermented papaya preparation for 30 days with immune-marker and gut-microbiota analysis (Fujita et al. 2017, PLoS One).
Older patients fed long term through a feeding tube, given different doses of the preparation.
The preparation restored peripheral blood mononuclear cell killing activity, which was low at baseline, toward higher levels; no other immune markers changed. At 9 g a day it reduced the abundance of some gut bacteria. Chemical analysis found only small phenolic-acid metabolites. The study was funded by a company that makes the preparation.
Randomized, placebo-controlled crossover safety trial of a fermented papaya preparation 9 g a day for 8 weeks per arm with a 4-week washout (Mankowski et al. 2018, J Frailty Aging).
30 moderate-functioning older adults aged 70 to 100; 29 completed with 94% adherence.
The main purpose was safety. There were no adverse changes in blood chemistry and no serious adverse events, and adverse events did not differ from placebo. There were no significant effects on body measurements, metabolic outcomes or markers of inflammation. The authors concluded the preparation is safe and feasible in this age group and called for trials in people with poorer health.
Multicentre, double-blind, placebo-controlled randomized trial of papaya leaf extract tablets three times a day for five days added to standard care (Kasture et al. 2016, J Assoc Physicians India).
300 patients with dengue fever and low platelet counts across five centers in India, managed under standard dengue guidelines.
Platelet counts rose faster with the leaf extract than with control, and side effects (nausea, vomiting) were similar in both groups. This is included to show the setting in which papaya leaf has been tested, which is medical care for an illness. NutraSmarts makes no claim that papaya treats dengue or raises platelets, and dengue requires medical care.